Literature DB >> 2349080

Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China.

Z Y Wang1, G L Sun, J X Lu, L J Gu, M E Huang, S R Chen.   

Abstract

Seventy patients with acute promyelocytic leukemia (APL) were entered in this study. Fifty-seven cases received all-trans retinoic acid (RA) as sole agent and 48 cases (84.2%) attained complete remission (CR) in about 42 days. While the other 8 cases (14%) obtained partial remission (PR) during some time. Thirteen patients received combinations of RA and chemotherapy. 9 cases (69.2%) attained CR in about two months and 4 other cases (30.8%) got PR. Total CR rate reached 95.9% after continuing the treatment. Fifty cases were closely followed after CR. Three kinds of continuation therapy were administered including RA as sole agent (Group A), chemotherapy alone (Group B) and RA and chemotherapy alternatively (Group C). The results showed Group C gave the longest duration of CR and longest duration of survival.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2349080

Source DB:  PubMed          Journal:  Nouv Rev Fr Hematol


  11 in total

1.  Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia.

Authors:  Kazuyuki Sato; Hirotaka Sakai; Yusuke Saiki; Akiko Uchida; Yu Uemura; Satoshi Yokoi; Yuka Tsuruoka; Yuji Nishio; Manabu Matsunawa; Yoshinori Suzuki; Yasushi Isobe; Masayuki Kato; Naoto Tomita; Yasuyuki Inoue; Ikuo Miura
Journal:  Int J Hematol       Date:  2018-05-29       Impact factor: 2.490

Review 2.  Retinoic acid, CYP26, and drug resistance in the stem cell niche.

Authors:  Salvador Alonso; Richard J Jones; Gabriel Ghiaur
Journal:  Exp Hematol       Date:  2017-07-25       Impact factor: 3.084

3.  Retinoic acid in the treatment of acute promyelocytic leukemia: inefficacy of the 13-cis isomer and induction of complete remission by the all-trans isomer complicated by thromboembolic events.

Authors:  V Runde; C Aul; T Südhoff; A Heyll; W Schneider
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

4.  Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.

Authors:  T Haferlach; W Gassmann; H Löffler; C Jürgensen; J Noak; W D Ludwig; E Thiel; D Haase; C Fonatsch; R Becher
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

Review 5.  Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.

Authors:  Junmin Li; Hongming Zhu; Jiong Hu; Jianqing Mi; Saijuan Chen; Zhu Chen; Zhenyi Wang
Journal:  Int J Hematol       Date:  2014-06-18       Impact factor: 2.490

6.  Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia.

Authors:  W H Miller; A Kakizuka; S R Frankel; R P Warrell; A DeBlasio; K Levine; R M Evans; E Dmitrovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

7.  A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma.

Authors:  Kimberly B Higginbotham; Richard Lozano; Thomas Brown; Yehuda Z Patt; Takashi Arima; James L Abbruzzese; Melanie B Thomas
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-27       Impact factor: 4.553

Review 8.  Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells.

Authors:  J W Zhang; J Y Wang; S J Chen; Z Chen
Journal:  J Biosci       Date:  2000-09       Impact factor: 2.795

9.  All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment.

Authors:  Meng Su; Salvador Alonso; Jace W Jones; Jianshi Yu; Maureen A Kane; Richard J Jones; Gabriel Ghiaur
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

Review 10.  History of Acute Promyelocytic Leukemia.

Authors:  Miguel A Sanz; Eva Barragán
Journal:  Clin Hematol Int       Date:  2021-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.